Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
about
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalEmerging molecularly targeted therapies in castration refractory prostate cancerRhoA as a mediator of clinically relevant androgen action in prostate cancer cellsSox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancerMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantTargeting bone physiology for the treatment of metastatic prostate cancerQuality of life issues in men undergoing androgen deprivation therapy: a reviewPotential molecular targeting of splice variants for cancer treatmentMYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsEffect of small molecules modulating androgen receptor (SARMs) in human prostate cancer modelsGarcinia subelliptica Merr. (Fukugi): A multipurpose coastal tree with promising medicinal propertiesSECONDARY HORMONAL MANIPULATIONS IN THE TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCERAR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionTALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Nonsteroidal androgen receptor ligands: versatile syntheses and biological data.Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.Identification of a clinically relevant androgen-dependent gene signature in prostate cancerChemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparisonThe role of mRNA splicing in prostate cancer.Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promisesMolecular genetics of prostate cancer: new prospects for old challengesARN-509: a novel antiandrogen for prostate cancer treatmentMultimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayAbiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Targeted therapy in prostate cancer.Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancerCombination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.Castration-resistant prostate cancer: new science and therapeutic prospects.Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).Alternatively spliced androgen receptor variantsAndrogen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Methoxychalcone inhibitors of androgen receptor translocation and function.A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.
P2860
Q21091046-E00A67A4-F723-42B8-BE7A-E77DFC6B6C77Q21284745-152F57FD-4F94-47FC-9FC3-4FA8F877B5ADQ24618899-7CF0E29E-2F13-4699-9880-E6F363CFBA1DQ24633279-BE864BE2-268D-41DB-8FCA-2B7B4A92383BQ26851177-1578973B-116E-43E8-B82C-B0DB1CD731A2Q26863249-AF7A283B-4163-4238-B047-2D02F4BD41D8Q27002887-1A7D21AB-6120-4B07-B21F-37D24C04BA15Q27008529-92104D7E-7931-4B1A-ACB4-151254EB4DB4Q27350187-3B0F8CCB-1B9D-4072-B569-977312DCDE87Q28487784-0B2B33FF-B838-4ABA-8CB3-A705BA168391Q28817605-EFB88721-0286-4290-9B8D-ACC6E43F8C33Q29302403-CAA4EC30-8709-43D3-B49F-25F55A6100D9Q30513836-33869E12-31AB-44F4-9325-B6A536BCF6D1Q30554439-46BD1D89-2B7A-441D-80C7-C99FB875FA4CQ30829176-442A8A95-3538-4B06-BE82-8818333783A6Q30847864-D635F0DB-7831-4F5C-9567-BB9103706C32Q33706967-682C339F-358D-4419-9AA7-7F4657D6F36BQ33821752-802AAD78-3392-46F2-9EF4-059B662F3A11Q33829606-A7D085D4-E3A0-403A-98D6-9FF27789C09EQ33922376-45990E4A-EDE8-44E3-AF75-ECF784FA5103Q33989603-C1A59A3A-C749-4326-8C9C-9A185E870B9AQ34002823-7EDF3210-CAC7-42B3-98F7-B3D4FE347EA2Q34127462-CBAA1F0D-AD99-476C-85D1-17DCFAB95F99Q34248790-6D68FBFA-EEAF-4137-9975-560A1A710001Q34310067-7CD9EEEF-A94E-4E5D-9496-B389992F9F1BQ34363785-B897D743-CFF0-4717-9B84-96818E719850Q34375823-0C87E1E4-2D8D-48F3-B013-9EE45436FB4AQ34417815-5E0DE946-CF82-4DA8-B006-71FA45B3D404Q34444867-F910C290-F11F-4464-A5CF-AF6FAAC82307Q34619574-421E5658-AF3D-44D5-9FCB-A8C78A3B8D51Q34634763-7C421E02-04A9-43ED-8028-58E5788A6622Q34996358-F917D0B1-D5A9-4C44-ADDF-B7FB934A41F1Q35018858-D5544BBF-CF6A-4864-AF23-01A5F4CA114FQ35076264-C210BAD1-B867-41DC-8FB8-312D7BA63187Q35213324-6BA64A62-F401-4547-810B-94B963A5991FQ35606969-3CA9F361-AF3A-418D-83E4-72DA25895AD2Q35740095-440DE60C-D043-4326-B157-33B24BD63622Q35794952-46CF59D9-D344-4507-AEF0-89130FDCB2B6Q35841689-8A40E2C5-6875-4A5A-A754-F3A72BA33E16Q35990121-D16665C4-6626-4BD9-805F-47377F1E4CB4
P2860
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-androgens and androgen-de ...... ents for an established target
@en
Anti-androgens and androgen-de ...... nts for an established target.
@nl
type
label
Anti-androgens and androgen-de ...... ents for an established target
@en
Anti-androgens and androgen-de ...... nts for an established target.
@nl
prefLabel
Anti-androgens and androgen-de ...... ents for an established target
@en
Anti-androgens and androgen-de ...... nts for an established target.
@nl
P2093
P2860
P1433
P1476
Anti-androgens and androgen-de ...... ents for an established target
@en
P2093
Howard I Scher
Nicola J Clegg
P2860
P304
P356
10.1016/S1470-2045(09)70229-3
P577
2009-10-01T00:00:00Z